BRIDGEBIO PHARMA INC. - COMMON STOCK

28.85

07-January-25 16:45:00

15 minutes delayed

Stocks

+0.59

+2.09%

Today's range

28.17 - 28.97

ISIN

N/A

Source

NASDAQ

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

23 Jul 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 16:31:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

06 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

04 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

03 Jun 2024 16:01:00 By Nasdaq GlobeNewswire
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

29 May 2024 16:01:00 By Nasdaq GlobeNewswire
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

24 May 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 May 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

14 May 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

13 May 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

02 May 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

02 May 2024 07:00:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

07 Apr 2024 13:15:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

05 Mar 2024 23:53:56 By Nasdaq GlobeNewswire
BridgeBio Pharma Announces Proposed Public Offering of Common Stock

04 Mar 2024 16:17:36 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.